Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 784Lung Neoplasms 346Ovarian Neoplasms 323Breast Neoplasms 279Fallopian Tube Neoplasms 159Triple Negative Breast Neoplasms 146Small Cell Lung Carcinoma 146Neoplasms 137Squamous Cell Carcinoma of Head and Neck 123Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 86Head and Neck Neoplasms 80Endometrial Neoplasms 77Uterine Cervical Neoplasms 72Esophageal Neoplasms 72Adenocarcinoma of Lung 71Neuroblastoma 55Central Nervous System Neoplasms 53Carcinoma 50Lymphoma, Large B-Cell, Diffuse 49Recurrence 48Brain Neoplasms 48Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Stomach Neoplasms 31

Interventions

tislelizumab 1selinexor 1atezolizumab 1anlotinib 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Cancer × Carboplatin × Clear all
NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
165 enrolled

Extensive Stage Lung Small Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡